GeneTx Biotherapeutics
Jul 24, 2021
Angelman syndrome Pipeline: Unmet needs call for a robust pipeline
The necessity of a robust Angelman syndrome pipeline is indispensable at the current moment because of a shortage of any approved therapy option available in the market. The Angelman Syndrome current treatment landscape consists of symptomatic therapy options worth USD 330.2 million in 2017. Treatment entire...
Read More...
-Agonist.png "Toll-like Receptors Agonist")
